What does the future hold for companies of the in vitro diagnostics (IVD) industry? Visiongain’s new report Medical Devices Leader Series – Top In Vitro Diagnostics (IVD) Companies 2017-2027: Leading IVD Companies in the US, Europe and Asia shows you the prospects of leading IVD companies to 2027.
Visiongain predicts total revenues the global IVD market will grow from its 2016 level of $61.85bn to $122.9bn by 2027, representing a CAGR of 6.4% during the period 2016 to 2027.
Our report forecasts to 2027 the overarching IVD market and its main segments: • Point-of-care (POC) tests • Clinical chemistry • Immunochemistry • Haematological diagnostics • Microbiological applications • Genetic testing agents • Other products
This report provides profiles, discussions and financial analyses – including revenue forecasts to 2027 – for top US IVD companies: • Danaher • Abbott Laboratories • Johnson & Johnson (J&J) • Bio-Rad • Becton Dickinson • Thermo Fisher Scientific
Our report shows you developments and revenue forecasts to 2027 for leading diagnostics companies based in Europe: • Roche • Siemens • bioMérieux
This report also provides outlooks and revenue forecasts to 2027 for top Japanese companies developing and producing IVD tests: • Sysmex • Arkray
Our work assesses other companies progressing in that field. There you discover activities of these emerging players and their associated organisations: • Dako (Agilent Technologies) • Genomic Health • Laboratory Corporation of America (LabCorp) • MDxHealth • Myriad Genetics • QIAGEN
Our 185 page report provides 65 tables and 75 figures covering 7 different IVD submarkets, leading companies in the US, Europe and Asia.
Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, industry trends, opportunities, and revenue predictions. The increasing prevalence of both chronic and infectious diseases will ensure that there is a great demand for use and innovation of IVDs over the next decade and beyond.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 How This Report Delivers Information 1.2 Main Questions This Report Answers 1.3 Who is This Report For? 1.4 Methods of Research and Analysis 1.5 Frequently Asked Questions (FAQs) 1.6 Some Related Reports 1.7 About Visiongain
2. An Introduction to In Vitro Diagnostics 2.1 The In Vitro Diagnostics Market 2.1.1 The In Vitro Diagnostics Market in 2017 2.2 What are In Vitro Diagnostic (IVD) Tests? 2.3 Classifying In Vitro Diagnostics 2.3.1 The US Classification 2.3.2 The EC (European Commission) Classification 2.3.3 Regulatory Issues in the IVD Market 2.3.3.1 Regulation of IVD Tests 2.3.3.2 Lack of Clarity Can be Costly 2.4 Types of IVD Test 2.4.1 Point of Care Diagnostics 2.4.2 Clinical Chemistry 2.4.3 Microbiology 2.4.3.1 Regulatory Differences with IVD Microbiology Tests 2.4.4 Haematology 2.4.5 Immunochemistry 2.4.6 Genetic Testing 2.5 The IVD Market: Overall Revenue Forecast to 2027 2.5.1 Market Drivers, 2016-2027 2.5.2 Market Restraints, 2016-2027 2.5.3 Future of the IVD Industry 2.6 Company Comparison 2.6.1 Fragmented Market 2.6.2 IVD Market: Leading Manufacturers in 2016
3. The Leading US In Vitro Diagnostic Companies, 2016-2027 3.1 Danaher 3.1.1 Sales and Recent Performance Analysis 3.1.2 Life Sciences and Diagnostics 3.1.3 Key Products 3.1.4 Danaher Manufacturing Capabilities 3.1.5 Danaher IVD Segment: Strengths and Challenges 3.1.6 Danaher’s Life Sciences and Diagnostics Revenues 3.1.6.1 IVD Revenue Forecast, 2016-2027 3.1.7 Recent Mergers and Acquisition (M&A) Activity 3.2 Abbott Laboratories 3.2.1 Sales and Recent Performance Analysis 3.2.2 Abbott: Diagnostics Segment 3.2.2.1 In Vitro Diagnostics Products 3.2.3 Abbott IVD Segment: Strengths and Challenges 3.2.4 Abbott Diagnostics Historical Revenues, 2013-2015 3.2.5 IVD Revenue Forecast, 2016-2027 3.2.6 Recent M&A Activity and Strategic Collaborations 3.2.6.1 Collaboration with GSK 3.2.6.2 Collaboration with Merck 3.2.6.3 Acquisition of STARLIMS Technologies 3.2.6.4 Acquisition of Ibis Biosciences, Inc. 3.2.7 Plans to Separate into Two Publicly Traded Companies 3.3 Johnson & Johnson (J&J) 3.4 Bio-Rad 3.4.1 Sales and Recent Performance Analysis 3.4.2 Clinical Diagnostics 3.4.2.1 In Vitro Diagnostics 3.4.3 IVD Revenue 2015 3.4.4 IVD Revenue Forecast, 2017-2026 3.4.5 Recent M&A Activity and Strategic Collaborations 3.4.6 Potential Bio-Rad Labs Takeover Seen in Near-Term 3.5 Becton Dickinson 3.5.1 Global Presence 3.5.2 Distribution 3.5.3 R&D 3.5.4 Sales and Recent Performance Analysis 3.5.4.1 Historical Sales Performance Analysis 3.5.5 BD Diagnostics Revenue 3.5.6 IVD Revenue Forecast, 2017-2027 3.5.7 Recent M&A Activity and Strategic Collaborations 3.6 Thermo Fisher Scientific 3.6.1 Historical Sales and Recent Performance Analysis 3.6.2 Clinical Diagnostics 3.6.3 Key Products 3.6.4 Thermo Fisher’s Manufacturing Capabilities 3.6.5 Thermo Fisher’s Diagnostics Revenues 3.6.6 IVD Revenue Forecast 2016-2027 3.6.7 Recent Mergers and Acquisition Activity 3.6.7.1 Acquisition of Dionex and Phadia
4. The Leading European In Vitro Diagnostic Companies, 2016-2027 4.1 Roche 4.1.1 Global Presence 4.1.2 Sales and Recent Performance Analysis 4.1.3 Roche Diagnostics 4.1.4 R&D Capabilities 4.1.5 Growing Portfolio of Diagnostic Products 4.1.5.1 Exploring Strategies in the Neurological Sector 4.1.6 IVD Revenue Forecast 2016-2027 4.1.7 Recent M&A Activity and Strategic Collaborations 4.1.7.1 Roche Offers to Acquire Illumina to Strengthen its Leading Position in Diagnostics 4.2 Siemens 4.2.1 Sales and Recent Performance, 2015 4.2.2 Siemens Healthcare 4.2.2.1 Siemens Diagnostics 4.2.2.2 Outperforming the Market 4.2.2.3 In Vitro Diagnostics 4.2.3 IVD Revenue Forecast 2016-2027 4.2.4 Recent M&A Activity and Strategic Collaborations 4.2.4.1 Partnership with ViiV Healthcare 4.2.4.2 Partnership with Tocagen 4.3 bioMérieux 4.3.1 Sales and Recent Performance, 2015 4.3.2 IVD Revenue Forecast 2016-2027 4.3.3 Recent M&A Activity and Strategic Collaborations 4.3.3.1 Partnership with GSK 4.3.3.2 Partnership with Ipsen 4.3.3.3 Partnership with Institute Merieux and Institute Pasteur 4.3.3.4 Collaboration with Hospices Civils de Lyon 4.3.3.5 Acquisition of ARGENE 4.3.3.6 Equity Interest in Knome
5. The Leading Japanese In Vitro Diagnostic Companies, 2016-2027 5.1 Sysmex 5.1.1 Global Presence and Distribution 5.1.2 Sales and Recent Performance Analysis 5.1.3 Sysmex Diagnostics 5.1.4 IVD Revenue Forecast 2016-2027 5.1.5 Recent M&A Activity and Strategic Collaborations 5.1.5.1 Acquisition of Katakura’s Research Institute of Biological Science 5.1.5.2 Collaboration with IDEXX Labs to Expand into Animal Diagnostics 5.2 Arkray 5.2.1 Global Presence 5.2.2 R&D 5.2.3 IVD Product Portfolio 5.2.4 Sales and Recent Performance Analysis 5.2.5 IVD Revenue Forecast 2016-2027
6. Emerging In Vitro Diagnostic Companies, 2017 6.1 Pipeline and Other Companies: An Overview, 2017 6.2 Other Prominent In Vitro Diagnostic Players 6.3 Dako (Agilent Technologies) 6.3.1 Sales and Recent Performance Analysis 6.3.2 M&A Activity and Other Key Developments 6.4 Genomic Health 6.4.1 Sales and Recent Performance Analysis 6.4.2 R&D Capabilities 6.4.2.1 TAILORx Clinical Trial 6.4.2.2 RxPonder Trial 6.4.2.3 Partnership with Oncomed 6.5 Laboratory Corporation of America (LabCorp) 6.5.1 Sales and Recent Performance Analysis 6.5.2 In Vitro Diagnostics 6.6 Recent M&A Activity and Other Key Developments 6.6.1 Agreement with Medco Health Sciences 6.6.2 Acquisition of Monogram Biosciences 6.6.3 Non-Exclusive License Agreement with Merck 6.6.4 Acquisition of Genzyme Genetics 6.6.5 Partnership with ARCA Biopharma 6.7 MDxHealth 6.7.1 Sales and Recent Performance Analysis, 2015 6.7.2 R&D Capabilities 6.7.3 In Vitro Diagnostics 6.7.3.1 PharmacoMDx 6.7.3.2 PredictMDx for Brain Cancer 6.7.3.3 PredictMDx for Colon Cancer 6.7.3.4 Partnership with GSK 6.8 Myriad Genetics 6.8.1 Sales and Recent Performance Analysis 6.8.2 R&D Capabilities 6.8.3 In Vitro Diagnostics 6.8.3.1 Myriad RBM 6.8.4 M&A Activity and Recent Partnerships 6.8.4.1 Agreement with BioMarin Pharmaceutical 6.8.4.2 Acquisition of Myriad RBM 6.8.4.3 Strategic Debt Investment in Crescendo Bioscience 6.8.4.4 Agreement with Cephalon 6.8.4.5 Agreement with PharmaMar 6.9 QIAGEN 6.9.1 Sales and Recent Performance Analysis 6.9.2 Continued Expansion in the Emerging Markets 6.9.3 R&D Capabilities 6.9.3.1 More than 15 Projects to Co-Develop and Market Diagnostic Products 6.9.3.2 Provider of Choice for Molecular Diagnostic Tools 6.9.4 Recent M&A Activity and Other Developments 6.9.4.1 Acquisition of Cellestis Ltd. 6.9.4.2 Acquisition of Ipsogen 6.9.4.3 Partnership with Pfizer 6.9.4.4 Partnership with Eli Lilly 6.9.4.5 Acquisition of SABiosciences Corporation 6.9.4.6 Acquisition of DxS Ltd (Now QIAGEN Manchester) 6.9.4.7 Acquisition of Explera s.r.l
7. Conclusions 7.1 In Vitro Diagnostics: Attractive Segment of the Healthcare Market 7.2 Big Pharma Dominated the IVD Market in 2015 7.3 The Rise of ‘Generic Medical Devices’ 7.4 What Will Succeed in the IVD Market? 7.5 Small Companies Can Have a Big Impact on the Industry and Market to 2027
Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form
Table of Figures Figure 2.1 IVD Market ($bn) by Class 2017 Figure 2.2 IVD: Overall Market ($bn) Forecast , 2016, 2017, 2021 & 2027 Figure 2.3 IVD Market: Drivers and Restraints, 2016-2027 Figure 2.4 Leading Companies in the IVD Market: Net Sales ($bn), 2016 Figure 2.5 Leading Companies in the IVD Industry: Market Shares (%), 2016 Figure 3.1 Danaher: Net Sales ($bn) by Business Segment, 2015 Figure 3.2 Danaher: Revenue Shares (%) by Business Segment, 2015 Figure 3.3 Danaher: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027 Figure 3.4 Danaher: IVD Market Share (%), 2016-2027 Figure 3.5 Abbott: Net Sales ($bn) by Business Segment, 2015 Figure 3.6 Abbott: Revenue Shares (%) by Business Segment, 2015 Figure 3.7 Abbott IVD Historical Performance 2012-2015: Revenue ($bn), AGR (%) Figure 3.8 Abbott: Revenues ($bn) by Region, 2015 Figure 3.9 Abbott: Revenue Shares (%) by Region, 2015 Figure 3.10 Abbott: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027 Figure 3.11 Abbott: IVD Market Share (%), 2016-2027 Figure 3.12 Bio-Rad: Historical Diagnostics Revenues ($bn), AGR (%), 2013-2015 Figure 3.13 Bio-Rad: Revenue Shares (%) by Business Segment, 2015 Figure 3.14 Bio-Rad: Revenue Shares (%) by Region, 2015 Figure 3.15 Bio-Rad: IVD Revenue Forecast ($bn), AGR (%), 2016-2027 Figure 3.16 Bio-Rad: IVD Market Share (%), 2016-2027 Figure 3.17 BD: Company Revenue ($bn), 2013-2015 Figure 3.18 BD IVD Revenue Forecast ($bn), AGR (%), 2016-2027 Figure 3.19 BD: IVD Market Share (%), 2016-2027 Figure 3.20 Thermo Fisher: IVD Net Sales ($bn), 2013-2015 Figure 3.21 Thermo Fisher: Revenue Shares (%) by Sector, 2015 Figure 3.22 Thermo Fisher: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027 Figure 3.23 Thermo Fisher: IVD Market Share (%), 2016-2027 Figure 3.24 Thermo Fisher: Mergers & Acquisitions Figure 4.1 Roche: Revenues ($bn) by Sector, 2015 Figure 4.2 Roche: Revenue Shares (%) by Sector, 2015 Figure 4.3 Roche Diagnostics: Revenue Shares (%) by Region, 2015 Figure 4.4 Roche Diagnostics: Revenues ($bn) by Sector, 2015 Figure 4.5 Roche Diagnostics: Revenue Shares (%) by Sector, 2015 Figure 4.6 Roche: IVD Revenue ($bn), AGR (%), Forecast, 2016-2027 Figure 4.7 Roche: IVD Market Share (%), 2016-2027 Figure 4.8 Siemens: Revenue Shares (%) by Sector, 2015 Figure 4.9 Siemens Healthcare: Revenue Shares (%) by Region, 2015 Figure 4.10 Siemens: IVD Revenue ($bn), AGR (%), Forecast 2016-2027 Figure 4.11 Siemens: IVD Market Share (%), 2015-2027 Figure 4.12 bioMérieux: Revenue ($bn) by Sector, 2015 Figure 4.13 bioMérieux: Revenue Shares (%) by Sector, 2015 Figure 4.14 bioMérieux: Clinical Applications Revenue ($bn) by Sector, 2015 Figure 4.15 bioMérieux: Clinical Applications Revenue Shares (%) by Sector, 2015 Figure 4.16 bioMérieux: IVD Revenue ($bn), AGR (%), Forecast, 2016-2027 Figure 4.17 bioMérieux: IVD Market Share (%), 2016-2027 Figure 5.1 Sysmex: Revenues ($m) by Sector, 2015 Figure 5.2 Sysmex: Revenue Shares (%) by Sector, 2015 Figure 5.3 Sysmex: Net Sales (%) by Geographical Region, 2015 Figure 5.4 Sysmex: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027 Figure 5.5 Sysmex: IVD Market Share (%), 2016-2027 Figure 5.6 Arkray: IVD Revenue ($bn) Forecast, AGR (%), 2016-2027 Figure 5.7 Arkray: IVD Market Share (%), 2015-2027 Figure 6.1 Aglient: Revenue ($bn) by Sector, 2015 Figure 6.2 Dako: Revenue Shares (%) by Sector, 2015 Figure 6.3 Genomic Health: Historical Revenues ($m) and Net Income ($m), 2011-2015 Figure 6.4 Genomic Health: Revenue Shares (%) by Reporting Segment, 2015 Figure 6.5 Genomic Health: Historical R&D Expense ($m) and R&D as a Percentage of Net Sales (%), 2011-2015 Figure 6.6 LabCorp: Historical Revenue ($bn), Profit ($bn), 2011-2015 Figure 6.7 LabCorp: Revenues ($bn) by Reporting Segment, 2015 Figure 6.8 LabCorp: Revenue Shares (%) by Reporting Segment, 2015 Figure 6.9 MDxHealth: Revenues ($m) by Reporting Segment, 2016 Figure 6.10 MDxHealth: Revenue Shares (%) by Reporting Segment, 2015 Figure 6.11 Myriad: Historical Net Revenues ($m), 2012-2016 Figure 6.12 Myriad: Revenue Shares (%) by Sector, 2016 Figure 6.13 Myriad Molecular Diagnostics: Revenue Shares (%) by Product, 2016 Figure 6.14 Myriad Molecular Diagnostics: Revenue Shares (%) by Sector, 2016 Figure 6.15 Myriad: Historical R&D Investments ($m), 2012-2016 Figure 6.16 QIAGEN: Historical Revenue ($m), Net Income ($m), 2011-2015 Figure 6.16 QIAGEN: Revenues ($m) by Customer Class, 2015 Figure 6.17 QIAGEN: Revenue Shares (%) by Customer Class, 2015 Figure 6.18 QIAGEN: Revenue Shares (%) by Region, 2015 Figure 6.19 QIAGEN: Historical R&D Expense ($m) and R&D Expense as a Percentage of Net Revenue (%), 2013-2015 Figure 7.1 IVD Market: Overall World Revenue ($bn), (AGR%) 2016-2027 Figure 7.2 Leading Market Segment: Revenue ($bn) Forecasts, 2016-2027
List of Tables Table 2.1 IVD Revenues ($bn) and Market Shares (%) by Class, 2016-2017 Table 2.2 Advantages and Disadvantages of POC Diagnostics Table 2.3 IVD Tests: Overall World Market and Submarket Revenue Forecasts ($bn), 2016, 2017, 2021 & 2027 Table 2.4 Leading Manufacturers: IVD Market Share (%), 2016 Table 2.5 Leading Companies in the IVD Market: Net Sales ($bn) and Market Shares (%), 2016 Table 3.1 Danaher: Key Facts, 2016 Table 3.2 Danaher: Net Sales ($bn) and Revenue Shares (%) by Business Segment, 2015 Table 3.3 Danaher: Life Sciences & Diagnostics Revenue ($bn), AGR (%) 2013-2015 Table 3.4 Danaher: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027 Table 3.5 Abbott: Key Facts, 2016 Table 3.6 Abbott: Net Sales ($bn) and Revenue Shares (%) by Business Segment, 2015 Table 3.7 Abbott: Revenues ($bn) and Revenue Shares (%) by Geographical Region, 2015 Table 3.8 Abbott: Diagnostics Revenue ($bn), AGR (%), 2013-2015 Table 3.9 Abbott: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027 Table 3.10 Johnson & Johnson: Key Facts, 2016 Table 3.11 Bio-Rad: Key Facts, 2017 Table 3.12 Bio-Rad: Clinical Diagnostics Revenue ($bn), AGR (%), 2013-2015 Table 3.13 Bio-Rad: IVD Revenue Forecast ($bn), Growth (%), CAGR (%), Market Share (%), 2016-2027 Table 3.14 BD: Key Facts, 2016 Table 3.15 Becton Dickinson: Net Sales ($bn) and Revenue Shares (%) by Sector, 2015 Table 3.16 BD: Diagnostics Revenue ($bn), AGR(%), 2013-2015 Table 3.17 BD: IVD Revenue Forecast ($bn) Growth (%), CAGR (%), Market Share (%), 2016-2027 Table 3.18 Thermo Fisher: Key Facts, 2016 Table 3.19 Thermo Fisher: IVD Sales ($bn), AGR (%), 2013-2015 Table 3.20 Thermo Fisher: Net Sales ($bn) and Revenue Shares by product segment (%) by Sector, 2015 Table 3.21 Thermo Fisher: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027 Table 4.1 Roche: Key Facts, 2016 Table 4.2 Roche: Revenue ($bn) and Revenue Shares (%) by Sector, 2015 Table 4.3 Roche Diagnostics: Revenue ($bn) and Revenue Shares (%), by Region, 2015 Table 4.4 Roche Diagnostics: Revenue ($bn) and Revenue Shares (%) by Sector, 2015 Table 4.5 Roche Diagnostics: Marketed Diagnostic Products Table 4.6 Roche: IVD Revenue ($bn) Forecast, Growth (%), CAGR (%), Market Share (%) Forecast 2016-2027 Table 4.7 Siemens: Key Facts, 2016 Table 4.8 Siemens: Revenue ($bn) and Revenue Shares (%) by Sector, 2015 Table 4.9 Siemens: Revenue ($bn) and Revenue Shares (%) by Region, 2015 Table 4.10 Siemens: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027 Table 4.11 bioMérieux: Key Facts, 2016 Table 4.12 bioMérieux: Revenue ($bn) and Revenue Shares (%) by Sector, 2015 Table 4.13 bioMérieux: Clinical Applications Revenue ($bn) and Revenue Shares (%) by Sector, 2015 Table 4.14 bioMérieux: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027 Table 5.1 Sysmex: Key Facts, 2016 Table 5.2 Sysmex: Revenue ($m) by Sector, 2015 Table 5.3 Sysmex: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027 Table 5.4 Arkray: Key Facts, 2016 Table 5.5 Arkray: IVD Revenue ($bn), Growth (%), CAGR (%), Market Share (%), Forecast 2016-2027 Table 6.1 Aglient: Revenue ($bn) and Revenue Shares (%) by Sector, 2015 Table 6.2 Dako: Marketed Diagnostic Products, 2015 Table 6.4 Genomic Health: Revenue ($m) and Revenue Shares (%) by Reporting Segment, 2015 Table 6.5 Genomic Health: R&D Expense ($m) and R&D Expense as a Percentage of Sales (%), 2011-2015 Table 6.6 LabCorp: Revenues ($bn) and Revenue Shares (%) by Reporting Segment, 2015 Table 6.7 Selected List of LabCorp’s Menu of Diagnostic Products, 2015 Table 6.8 MDxHealth: Revenue ($m) and Revenue Shares (%) by Reporting Segment, 2015 Table 6.9 MDxHealth: In Vitro Diagnostics Pipeline, 2016 Table 6.10 Myriad: Revenue ($m) and Revenue Shares (%) by Sector, 2016 Table 6.11 Myriad Molecular Diagnostics: Revenue ($m) and Revenue Shares (%) by Product, 2016 Table 6.12 Myriad Molecular Diagnostics: Revenue ($m) and Revenue Shares (%) by Sector, 2016 Table 6.13 Myriad: Biomarker Product Portfolio, 2016 Table 6.14 Myriad: Diagnostic Products, 2016 Table 6.15 QIAGEN: Revenue ($m) and Revenue Shares (%) by Customer Class, 2015 Table 6.16 QIAGEN: Revenue ($m) and Revenue Shares (%) by Region, 2015 Table 6.17 QIAGEN: Selected List of Co-development Projects Table 6.18 QIAGEN: Selected Marketed Diagnostic Products, 2015 Table 6.19 QIAGEN: Recent M&A Activity Table 6.22 Other Companies Operating in the IVD Market, 2016 Table 7.1 Leading IVD Manufacturers by Company Type, 2016
3M AB Sciex Abbott Laboratories AbbVie Accuri Cytometers Agilent Technologies Alacris Theranostics GmbH Alere Amgen Analytical Technologies ARGENE Arkray AstraZeneca Banner Alzheimer’s Institute Bayer Bayer Diagnostics BD Pharmaceutical Systems BD Technologies Beckman Coulter Becton, Dickinson and Company (BD) BioMarin Pharmaceutical bioMérieux Bio-Rad Boehringer Ingelheim Bristol-Myers Squibb Cancer Research Technology Cardiogenics Carmel Pharma AB Celldex Therapeutics Cellestis Centre for Devices and Radiological Health (CDRH) Cephalon Claros Diagnostics Clearstone Central Laboratories CLIA laboratory Clovis Cole-Parmer Crescendo Bioscience Dako (Agilent Technologies) Danaher Dionex DxS (Now QIAGEN Manchester) Eli Lilly ESE GmbH Euronext Brussels European Commission European Diagnostic Manufacturers Association (EDMA) European Union (EU) Explera s.r.l Fermentas Fisher Scientific Food and Drug Administration (US FDA) Fujirebio Furuno Electric Co. Genentech Genomic Health GenProbe Genzyme Genetics GlaxoSmithKline (GSK) Hoffman La Roche Hologic Ibis Biosciences IDEXX Laboratories IGEN International Illumina Institut Pasteur Institute Merieux Instrumentation Labs Ipsen Ipsogen JEOL Ltd. John Hopkins University Johnson & Johnson (J&J) Katakura Industries KIESTRA Lab Automation Knome LabCorp Laboratory Corporation of America (LabCorp) Leica Biosystems Life Technologies Luminex Lyon Civil Hospitals MDS MDxHealth Medco Health Sciences Merck & Co. Mindray Miraca Life Sciences Monogram Biosciences Myriad Genetics Myriad RBM Nalgene Newcastle University Novartis Oncomed OncoMethylome Ortho-Clinical Diagnostics Pfizer Phadia Pierce Protein Research Polymedco Inc. QIAGEN QuantaLife Quest Diagnostics Radiometer Response Biomedical Corporation Roche Roche Applied Science Saladax Schering Plough SDIX Siemens Healthcare Sirigen Group Limited STARLIMS Technologies Surgipath SWOG Sysmex Corporation Sysmex Group Teva Pharmaceutical Industries Thermo Fisher Scientific Thermo Scientific TOA Corporation TOA Medical Electronics Tocagen Tosoh Transasia Bio Medicals Van Andel Research Institute Ventana Vermillion ViiV Healthcare
Download sample pages
Complete the form below to download your free sample pages for Medical Devices Leader Series: Top In Vitro Diagnostics (IVD) Companies 2017-2027
The Alzheimer’s Disease Therapeutics and Diagnostics Market will reach $7.93bn in 2018. The Alzheimer’s Disease Therapeutics and Diagnostics Market is...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
